BNKL insider filings
Bionik Laboratories Corp. — 18 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2023-06-21. Screen BNKL transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for BNKL between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — Bionik Laboratories Corp.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2023-06-21 | 4 | Gaston-Dreyfus Remi — Director, 10% owner | Conversion (C): 3,102,878 @ $0.60 | EDGAR |
| 2023-06-21 | 4 | AUBERTON-HERVE ANDRE-JACQUES — Director | Conversion (C): 186,111 @ $0.60 · Purchase (P): 1 (derivative) @ $220,000 | EDGAR |
| 2023-06-21 | 4 | Matine Charles — Director | Purchase (P): 180,555 @ $0.60 | EDGAR |
| 2023-06-21 | 4 | Gaston-Dreyfus Remi — Director, 10% owner | Purchase (P): 180,555 @ $0.60 | EDGAR |
| 2023-06-21 | 4 | AUBERTON-HERVE ANDRE-JACQUES — Director | Purchase (P): 650,000 @ $0.60 | EDGAR |
| 2022-10-13 | 4 | Russo Richard Paul Jr — CEO and President | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2022-06-21 | 4 | AUBERTON-HERVE ANDRE-JACQUES — Director | Option exercise (M): 51,878 @ $3.60 · Option exercise (M): 7,500 @ $3.16 · Option exercise (M): 51,878 (derivative) @ $0 · Option exercise (M): 7,500 (derivative) @ $0 | EDGAR |
| 2022-06-21 | 4 | Gaston-Dreyfus Remi — Director, 10% owner | Conversion (C): 77,887 @ $9.50 | EDGAR |
| 2021-12-13 | 4 | Gaston-Dreyfus Remi — Director, 10% owner | Option exercise (M): 115,759 · Option exercise (M): 5,000 · Option exercise (M): 115,759 (derivative) @ $0 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2021-12-13 | 4 | Gaston-Dreyfus Remi — Director, 10% owner | Grant/award (A): 61,256 | EDGAR |
| 2021-12-13 | 4 | Gaston-Dreyfus Remi — Director, 10% owner | Purchase (P): 135,560 | EDGAR |
| 2021-10-18 | 4 | Wass Loren W. — See Remarks | Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2021-10-15 | 4 | Russo Richard Paul Jr — CFO and Interim CEO | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2021-04-01 | 4 | AUBERTON-HERVE ANDRE-JACQUES — Chairman, Director | Purchase (P): 95,149 | EDGAR |
| 2021-03-31 | 4 | Thevenon Audrey — Director | Purchase (P): 26,430 | EDGAR |
| 2021-03-31 | 4 | Matine Charles — Director | Purchase (P): 26,430 | EDGAR |
| 2021-03-31 | 4 | MALONE PETER GERALD — Director | Purchase (P): 26,430 | EDGAR |
| 2021-03-31 | 4 | MARTIN JOSEPH R — Director | Purchase (P): 26,430 | EDGAR |
Recent 8-K events — Bionik Laboratories Corp.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2023-06-27 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-06-16 | 8-K | 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-06-16 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-06-15 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-05-23 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-05-04 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-04-26 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-02-23 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-02-08 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-01-20 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=BNKL returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs